United Therapeutics Corporation

UTHR

Held by 7 specialist biotech funds

High Convergence

7 funds opened new positions. Next phase2 readout: Jul 2010. Short interest: 9.8% of float.

BiotechnologyCEO: Martine A. RothblattIPO: 1999Website ↗

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Catalysts

Phase 3Q3 2008Oral treprostinil (UT-15C) sustained release tabletsPulmonary HypertensionNCT00325442

Primary: Six Minute Walk Distance (6MWD) (Baseline and 16 Weeks)Enrollment:354/354Sites: 72RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2010Muscle Loss, Muscle AnabolismNCT01366924

Primary: Change in muscle protein synthesis after exercise or exercise with amino acid supplementation. (An average change over a 210 minute recovery period from a 60 minute endurance exercise session)Enrollment:23/23Sites: 2RANDOMIZED, DOUBLE, BASIC_SCIENCE

Phase 2NegativeQ3 2010MAb-3F8Primary Refractory NeuroblastomaNCT00969722

Primary: To compare the proportion of patients achieving a complete bone marrow response measured by an absence of histological evidence of bone marrow disease and by MIBG scan after two cycles of treatment. (two years)Enrollment:1/1Sites: 15RANDOMIZED, TREATMENT

Phase 2Q3 2011LapatinibBreast CancerNCT00299286

Primary: Changes in Ki67 after short term treatment with lapatinib. (11-14 days after treatment)Enrollment:121/121Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ3 2011treprostinil diethanolamineSystemic SclerosisNCT00848107

Primary: Net Ulcer Burden- Mean Change From Time of Study Entry for Each Scheduled Visit Assessment (Baseline and Months 1, 3, 6, 9, 12, and 18)Enrollment:115/115Sites: 26NA, TREATMENT

Phase 3Q4 2011Chronic Obstructive Pulmonary Disease, Hypercapnic Respiratory FailureNCT01523470

Primary: Success of NIV withdrawal (an average of 4.5 day (6 days in stepwise group and 3 days in immediate group))Enrollment:60/60Sites: 1RANDOMIZED, TREATMENT

Phase 2Q4 2013UT-15C SRPulmonary Arterial HypertensionNCT01477333

Primary: Change in Hemodynamic Parameters From Baseline to Week 24. (Baseline and Week 24)Enrollment:18/18Sites: 6NA, TREATMENT

Phase 3Q4 2013KALOMIN™ Tab.Acute BronchitisNCT02151734

Primary: Total score of BSS(Bronchitis Severity Score) (7days)Enrollment:242/242RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2014DoxycyclineAdvanced Malignant Neoplasm, Dermatologic ComplicationNCT01867294

Primary: Number of Patients Reporting a Grade 2+ Adverse Event Attributed to Spironolactone (Study I) (At 8 weeks)Enrollment:19/19Sites: 5RANDOMIZED, SINGLE, SUPPORTIVE_CARE

Phase 3Q4 2014Cow Milk AllergyNCT02351531

Primary: Number of patients dropped out for intolerance (2 weeks)Enrollment:32/32Sites: 3NA, TREATMENT

Phase 3PositiveQ2 2018ApixabanCerebral Vein Thrombosis, Deep Vein Thrombosis, Gonadal ThrombosisNCT02585713

Primary: 6 Month Bleeding Rate (Up to 6 months)Enrollment:300/300Sites: 18RANDOMIZED, SUPPORTIVE_CARE

Phase 2Q2 2018Oral treprostinilPulmonary Hypertension, Pulmonary FibrosisNCT02603068

Primary: Change in pulmonary vascular resistance (PVR) (Baseline to Week 16)0Sites: 7RANDOMIZED, TREATMENT

Phase 2Q4 2018VinflunineLocally-advanced or Metastatic Penile NeoplasmsNCT02057913

Primary: Clinical Benefit (12 weeks)Enrollment:22/22Sites: 9NA, TREATMENT

Phase 2Q1 2019PembrolizumabMetastatic Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Carcinoma, Unresectable Small Intestinal CarcinomaNCT02949219

Primary: Overall Confirmed Response Rate (1 year (up to 18 cycles))Enrollment:41/41Sites: 8NA, TREATMENT

Phase 2Q3 2019Brentuximab VedotinAnn Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin LymphomaNCT02758717

Primary: Overall Metabolic Response Rate (Up to 8 cycles of treatment (approximately 29 weeks))Enrollment:46/46Sites: 9NA, TREATMENT

Phase 3NegativeQ4 2019Adenocarcinoma of the ProstateNCT03327662

Phase 3PositiveQ4 2019Inhaled TreprostinilPulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and EmphysemaNCT02630316

Primary: Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16 (Baseline and Week 16)Enrollment:326/326Sites: 97RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ4 2019DoseChronic Migraine, HeadacheNCT04349176

Primary: mean change in frequency of headache days for the baseline period compared to the 28-day period ending with week 24 (24 weeks)Enrollment:35/35Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 2PositiveQ3 2020SelumetinibMetastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland CarcinomaNCT02393690

Primary: Response at 6 Months (At 6 months)Enrollment:60/60Sites: 11RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2021Eribulin MesylateBreast Adenocarcinoma, HER2/Neu Negative, Invasive Breast CarcinomaNCT02037529

Primary: Cumulative Dose Level Triggering a Grade 2 or Higher Neuropathy Event. (6 months)Enrollment:201/201Sites: 39RANDOMIZED, TREATMENT

Phase 2Q1 2021FluorouracilMetastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction AdenocarcinomaNCT03337087

Primary: Number of Participants With Dose Limiting Toxicities (Phase I) (Up to 28 days from start of treatment)Enrollment:18/18Sites: 3NA, TREATMENT

Phase 3Q2 2021Fulvestrant 500mgBreast Neoplasm FemaleNCT03447132

Primary: pCR according to Le Chevalier's classification (up to 5 years after the end of treatment period)Enrollment:354/354Sites: 14RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2021UT-15C (treprostinil diolamine)Pulmonary Arterial HypertensionNCT01560637

Phase 2Q3 2021CarboplatinRecurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaNCT02628405

Primary: Overall Response Rate (Phase II) (At 42 days (after 2 courses) of treatment)Enrollment:30/30Sites: 12NA, TREATMENT

Phase 2Q4 2021Bladder CancerNCT02447549

Primary: Proportion of participants meeting predefined radiotherapy dose constraints in DART group (4-6 weeks from randomisation)Enrollment:345/345Sites: 49RANDOMIZED, TREATMENT

Phase 2Feb 10, 2022177Lu-J591Prostate CancerNCT00859781

Primary: Proportion of Participants Free of Radiographically Evident Metastases From Baseline to 18 Months After Study Drug Administration (Baseline and 18 months after study drug administration)Enrollment:55/55Sites: 9RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2022UI022 or UI023 and co-administration of matching placeboPeripheral Arterial DiseaseNCT07600385

Phase 2Q3 2022CyclophosphamideBilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7NCT03012100

Primary: Disease-free Survival (7 years)Enrollment:280/280Sites: 12RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q4 2022Yogurt smoothie with BB-12Metabolic SyndromeNCT03418857

Primary: Change from baseline in inflammatory markers (At baseline before intervention period 1, at endpoint of intervention period 1 (week 4), at baseline before intervention period 2 (week 8), at endpoint after intervention period 2 (week 12))Enrollment:Target 40Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Nov 15, 2022Critical Illness, Wounds and Injury, Disease AttributesNCT04534972

Primary: Supplemental Oxygen Free Days (SOFD) (up to 28 days)Enrollment:Target 2,000Sites: 6RANDOMIZED, TREATMENT

Phase 3Nov 15, 2022Critical Illness, Wounds and Injury, Disease AttributesNCT04534959

Primary: Supplemental Oxygen Free Days (SOFD) (up to 28 days)Enrollment:Target 6,000Sites: 8RANDOMIZED, TREATMENT

Phase 3NegativeQ4 2022Inhaled treprostinil solutionPulmonary Hypertension, Chronic Obstructive Pulmonary DiseaseNCT03794583

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (Up to 4 years)Enrollment:41/41Sites: 32NA, TREATMENT

Phase 2Q1 2023UB-421HIV-1 InfectionNCT05056974

Primary: HIV cell-associated RNA levels (Post-treatment weeks up to 48 weeks)Enrollment:11/11Sites: 1NA, TREATMENT

Phase 2Feb 17, 2023EnzalutamideBreast CancerNCT02955394

Primary: Number of Patients With a PEPI Score Equal to Zero at Post Treatment (16 Weeks)Enrollment:61/61Sites: 3RANDOMIZED, TREATMENT

Phase 2NegativeQ2 2023Abiraterone AcetateMetastatic Castration Resistant Prostate CancerNCT04458311

Primary: Phase I - To describe the safety and tolerability of abiraterone acetate and tildrakizumab when given in combination. To establish a RP2D for tildrakizumab, in combination with abiraterone. (20 months)Enrollment:13/13Sites: 6NON_RANDOMIZED, HEALTH_SERVICES_RESEARCH

Phase 2Q3 2023CetuximabBRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal AdenocarcinomaNCT04117945

Primary: Overall Survival (OS) (20 months)Enrollment:22/22Sites: 15RANDOMIZED, TREATMENT

Phase 2Q4 2023PanitumumabMetastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal AdenocarcinomaNCT03992456

Primary: Overall Survival (OS) (2 years)Enrollment:12/12Sites: 18RANDOMIZED, TREATMENT

Phase 2Jan 23, 2024[18F]PSMA-1007 InjectionProstate Cancer, Prostate Adenocarcinoma, Prostate NeoplasmNCT04053842

Primary: Pathologic Validation and Modeling (4 years)Enrollment:16/16Sites: 1NA, DIAGNOSTIC

Phase 2Q1 2024PalmidrolChemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid NeoplasmNCT05246670

Primary: Mean Change in Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 (CIPN20) Score (8 weeks)Enrollment:88/88Sites: 10RANDOMIZED, DOUBLE, SUPPORTIVE_CARE

Phase 3Q2 2024Aromatase InhibitorsBreast CancerNCT02338310

Primary: Time to recurrence (5 years post-randomisation)Enrollment:4,486/4,486Sites: 128RANDOMIZED, TREATMENT

Phase 2Jun 25, 2024N-Acetyl cysteineNeurofibromatosis 1NCT04481048

Primary: Change From Baseline in Motor Function Measured by Physical and Neurological Examination for Soft Signs (PANESS) (Baseline vs. end of treatment, 8 weeks)Enrollment:25/25Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2024Doxazosin Mesylate, Extended ReleaseStress Disorders, Post-TraumaticNCT03339258

Primary: Change in Clinician Administered PTSD Scale (CAPS) Distressing Dream Score (Baseline and Week 9 (end-of-treatment))Enrollment:Target 80Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2024Leukocyte-Poor Platelet Rich Plasma (LP-PRP)Osteoarthritis, KneeNCT04205656

Primary: Incidence of Treatment-Emergent Adverse Events (18 months)Enrollment:45/45Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 2Q3 2024PaclitaxelClinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8NCT04660760

Primary: Progression-free survival (Up to 1 year)Enrollment:Target 116Sites: 15RANDOMIZED, TREATMENT

Phase 2Q3 2024Brain Injuries, Traumatic, Brain Injuries, Acute, TBI (Traumatic Brain Injury)NCT02525432

Primary: Macro and micro structural properties of grey matter (GM) and white matter (WM) regions will measured using high-resolution anatomical MRI and diffusion tensorm imaging and comparisons made between groups. (up to 6 months. Post Head Injury)Enrollment:37/37Sites: 1RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q3 2024AcalabrutinibMantle Cell LymphomaNCT04626791

Primary: Percentage of Complete Responses to Therapy (Complete Metabolic Response [CMR]) (29 months)Enrollment:41/41Sites: 3NA, TREATMENT

Phase 2Aug 13, 2024CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA VaccineLung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8NCT05242965

Primary: CD8 is Reported as a Fraction of CD3+ Tumor Infiltrating Lymphocytes (TIL) in 4 High-power Field (HPF) (Baseline and after the third vaccine (at approximately 12 weeks))Enrollment:Target 40Sites: 2RANDOMIZED, DOUBLE, TREATMENT

Phase 2Aug 26, 2024MetforminC9orf72 Amyotrophic Lateral Sclerosis (ALS), Frontotemporal DementiaNCT04220021

Primary: Number of Subjects With Unexpected Treatment-emergent Adverse Events [Safety and Tolerability] (Baseline through 24 weeks)Enrollment:41/41Sites: 1NA, TREATMENT

Phase 3Sep 30, 2024IbuprofenPatent Ductus Arteriosus After Premature BirthNCT05011149

Primary: Proportion of eligible infants recruited during the study period (7 days postnatal age)Enrollment:Target 100Sites: 9RANDOMIZED, TREATMENT

Phase 2Q3 2024CarfilzomibRecurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaNCT04756401

Primary: Rate of Minimal Residual Disease (MRD) Negative Status (Up to 5 years post-treatment)Enrollment:8/8Sites: 4NA, TREATMENT

Phase 2Oct 31, 2024FisetinFemoroacetabular ImpingementNCT05025956

Primary: Incidence of Treatment-Emergent Adverse Events (From date of study drug dosing until the end of the study, an average of 12 months)Enrollment:Target 68Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Feb 6, 2025PembrolizumabBreast CancerNCT03366844

Primary: Number of Patients Who do Not Necessitate a Delay in Standard of Care Treatment After Receiving the Investigational Combination of Preoperative Pembrolizumab and Radiation (8 weeks after trial initiation)Enrollment:66/66Sites: 1NA, TREATMENT

Phase 3Q2 2025Idiopathic Pulmonary Fibrosis, Interstitial Lung DiseaseNCT05255991

Phase 2Jul 1, 2025TreprostinilIschemia Reperfusion Injury, Delayed Graft FunctionNCT04005469

Primary: Serum creatinine (SCr) (Day 1-7)Enrollment:Target 20Sites: 1NA, PREVENTION

Phase 2Q3 2025Brentuximab VedotinAnn Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin LymphomaNCT03233347

Primary: Progression Free Survival (3 years)Enrollment:83/83Sites: 9NA, TREATMENT

Phase 3Jul 9, 2025RegorafenibGastro-Oesophageal CancerNCT04879368

Primary: O/S (From the date of randomisation to date of death from any cause or the date last known alive, assessed up to approximately 44 months.)Enrollment:462/462Sites: 94RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2025IpilimumabBCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular CarcinomaNCT05199285

Primary: Confirmed objective response rate (ORR) (Up to 6 months)Enrollment:15/15Sites: 5NA, TREATMENT

Phase 2Sep 12, 2025CarboplatinRecurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal CarcinomaNCT04387227

Primary: Progression-free survival (At 6 months)Enrollment:22/22Sites: 1NA, TREATMENT

Phase 2Q3 2025CT-011Multiple MyelomaNCT01067287

Primary: First Stage: To explore immunological response to Pidilizumab (MDV9300) in the post-transplant period. (3 years)Enrollment:Target 35Sites: 3NON_RANDOMIZED, TREATMENT

Phase 2Q3 2025Cyclobenzaprine HClAcute Stress Reaction, Acute Stress Disorder, Neurocognitive FunctionNCT06636786

Primary: Change in ASD Score (Week 1, 3 after MVC)Enrollment:Target 180Sites: 9RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Oct 1, 2025CabozantinibAdvanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8NCT05361720

Primary: Overall response rate (ORR) (Arm 1) (Up to 4 years)Enrollment:Target 54Sites: 6NON_RANDOMIZED, TREATMENT

Phase 2Q4 2025DurvalumabStage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8NCT05194293

Primary: Objective Response Rate (ORR) (Unconfirmed) (16 weeks)Enrollment:4/4Sites: 3NA, TREATMENT

Phase 2Q4 2025UBT251 Injection 2.0 mg and UBT251 Injection PlaceboType 2 Diabetes Mellitus (T2DM)NCT07163624

Phase 2Dec 22, 2025DC1 VaccineBreast Cancer Female, Breast Cancer, Male, Breast Cancer Stage INCT03384914

Primary: Immunogenicity (Up to 3 years)Enrollment:119/119Sites: 7RANDOMIZED, TREATMENT

Phase 2Q4 2025UBT251 Injection 2.0 mg and UBT251 Injection PlaceboObesity &Amp; OverweightNCT07177469

Phase 2Q4 2025Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)Hormonal Receptors Positive, HER2 Negative, Advanced Breast CancerNCT05190094

Primary: Rate of Objective Clinical Response (From date of first treatment until the date of the first documented progression, assessed up to 2 years.)Enrollment:Target 80Sites: 7NA, TREATMENT

Phase 2Q4 2025Levoleucovorin CalciumAutism Spectrum Disorder, Language DisordersNCT04060017

Primary: Evaluate the change in measures of expressive language (Screening, Week 12, Week 24)Enrollment:Target 80Sites: 2RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Dec 31, 2025LofexidinePost Traumatic Stress Disorder, Opioid-use DisorderNCT04360681

Primary: Opioid Use (12 weeks)Enrollment:84/84Sites: 2RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2025AtezolizumabLocally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8NCT05168163

Primary: Overall survival (OS) (From randomization to death from any cause, assessed up to 3 years)Enrollment:Target 122Sites: 16RANDOMIZED, TREATMENT

Phase 2Q4 2025MultiStemTrauma, Adult Stem CellsNCT04533464

Primary: A composite of the highest Acute Kidney Injury stage (based on KDIGO guidelines) (Day 30)Enrollment:Target 156Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Jan 1, 2026TecovirimatSmallpoxNCT04957485

Primary: Adverse Events (59 Days)Enrollment:100/100Sites: 2RANDOMIZED, DOUBLE, TREATMENT

Phase 2Jan 1, 2026umbilical cord-derived mesenchymal stromal cells (UC-MSCs)Ischemic Heart DiseaseNCT06145035

Primary: change in LVEF (D LVEF) between baseline (M0) and 12 months after the first study product infusion (SPI) (M12) (Baseline, 12 months)Enrollment:Target 60Sites: 3RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2026AM3101Meniscus TearNCT05560477

Primary: Healing Assessed via MRI (12 months)Enrollment:Target 74Sites: 3RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Mar 30, 2026Abdominal TraumaNCT06065202

Primary: Change in six-minute walk distance (6 MWD) (3 months)Enrollment:Target 150Sites: 1RANDOMIZED, TREATMENT

Phase 2Mar 31, 2026Iodine-124Thyroid CancerNCT06961084

Primary: Proportion of agreement between I-124 PET and I-123/I-131 SPECT (participant) (1 day)Enrollment:Target 62Sites: 1NA, DIAGNOSTIC

Phase 2Mar 31, 2026Ibrutinib 560 mgMantle Cell LymphomaNCT04802590

Primary: Minimum residual disease (MRD) rate (6 months)Enrollment:210/210Sites: 45RANDOMIZED, TREATMENT

Phase 2Q1 2026177Lu-PSMA-617Metastatic Hormone Naive Prostate CancerNCT04343885

Primary: Undetectable prostate specific antigen (PSA) rate at 12 months after commencement of protocol therapy (Upto 32 months assuming 18 months to complete recruitment, a maximum of 1.6 months from consent to commencement of treatment for last patient and then 12 months from commencement of treatment for last patient.)Enrollment:130/130Sites: 12RANDOMIZED, TREATMENT

Phase 2Q1 2026ipatasertibSolid Tumor, Glioblastoma Multiforme, Prostate Cancer MetastaticNCT03673787

Primary: To identify a maximum tolerated dose in Phase I (12 months)Enrollment:Target 87Sites: 1NON_RANDOMIZED, HEALTH_SERVICES_RESEARCH

Phase 2Apr 30, 2026cyclophosphamideMalignant Pleural Disease, Mesothelioma, MetastasesNCT02414269

Primary: Composite measure of severity and number of adverse events (AEs); changes in (clinical laboratory test findings (hematologic and chemistry); and physical examination. (Phase I) (1 year)Enrollment:113/113Sites: 6NON_RANDOMIZED, TREATMENT

Phase 2May 29, 2026rF1V-1018Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia PestisNCT07207408

Primary: Anti-rF1V antibody level (4 weeks after final study vaccine)Enrollment:Target 148Sites: 4RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3Q2 2026Spinal Cord InjuriesNCT04782947

Primary: Change in 10-meter over ground walking-speed (Baseline to 12 months)Enrollment:Target 20Sites: 1RANDOMIZED, HEALTH_SERVICES_RESEARCH

Phase 2Jun 1, 2026Clemastine FumarateMultiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary ProgressiveNCT05359653

Primary: Corpus Callosum Myelin Water Fraction (This will be assessed at the baseline visit.)Enrollment:Target 74Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Jun 1, 2026KetamineMultiple Sclerosis FatigueNCT05378100

Primary: Modified Fatigue Impact Scale (MFIS) Score (Baseline (infusion visit) through four weeks after the infusion.)Enrollment:Target 110Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Jun 30, 2026LinaclotideColorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8NCT03796884

Primary: Pharmacodynamics effect on cGMP levels (Up to 2 years, plus an additional 12 months for primary analysis)Enrollment:150/150Sites: 3RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2026UB-421HIV-1 InfectionNCT04406727

Phase 3Jun 30, 2026Lopinavir-RitonavirSevere Acute Respiratory SyndromeNCT04381936

Primary: Community-acquired pneumonia: All-cause mortality (with subsidiary analyses of cause of death and of death at various timepoints following discharge) (Within 28 days after randomisation)Enrollment:Target 70,000Sites: 16RANDOMIZED, TREATMENT

Phase 2Jun 30, 2026DexamethasoneVoice Change, HypocalcemiaNCT05732883

Primary: Post-operative calcium and parathyroid hormone level on POD1 (Post-op 1 day)Enrollment:Target 100Sites: 1RANDOMIZED, TRIPLE, PREVENTION

Phase 2Q2 2026Enzalutamide 40mgMetastatic Castration-Resistant Prostate Cancer (m CRPC)NCT06126731

Primary: Confirm the safety and tolerability of the combination of amoxicillin plus metronidazole (2 weeks) followed by ciprofloxacin plus vancomycin (2 weeks) along with enzalutamide in Phase I in mCRPC patients. (28 days)Enrollment:Target 39Sites: 2NA, TREATMENT

Phase 3Q2 2026Autism Spectrum DisorderNCT05268796

Primary: Frequency of challenging behavior (4 week intervals)Enrollment:Target 90Sites: 2RANDOMIZED, SINGLE, TREATMENT

Phase 3Q2 2026Inhaled TreprostinilIdiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary FibrosisNCT04905693

Primary: Long-term safety and tolerability of inhaled treprostinil in subjects with IPF or PPF (Baseline to 6 years)Enrollment:Target 1,850Sites: 193NA, TREATMENT

Phase 2Jul 1, 2026cP12Thermal BurnsNCT06814717

Primary: Incidence and severity of adverse events from dosing through follow-up (Day 1, Day 3 and Day 14)Enrollment:Target 6Sites: 1NA, OTHER

Phase 2Jul 31, 2026Infusion of 5 mg/kg InfliximabAcute PancreatitisNCT03684278

Primary: Difference in mean serum CRP measured on days 2, 4 and 14 (Days 2, 4 (+/- 1 day), and 14 (+/- 2 days))Enrollment:Target 240Sites: 14RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2026Tranexamic AcidSpinal Injuries, Spinal DeformityNCT02314988

Primary: Maximal drop in systemic hemoglobin concentration during the postoperative period (Patients will be followed through postoperative day 4)Enrollment:Target 252Sites: 4RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q3 2026Tobramycin InjectionWound Infection, Fractures, Open, Surgical Site InfectionNCT04964947

Primary: Rate of infection (1 year)Enrollment:600/600Sites: 3RANDOMIZED, TREATMENT

Phase 2Q3 2026Recombinant human growth hormoneGulf War Syndrome, Adult Growth Hormone DeficiencyNCT05355272

Primary: Change in truncal fat mass from baseline to six months (6 months)Enrollment:Target 20Sites: 2NA, TREATMENT

Phase 2Q3 2026Post-Concussion Syndrome, Concussion, Brain, Mild Traumatic Brain InjuryNCT06073886

Primary: Central target engagement, modulation, and durability (Change from baseline across all subsequent time points until completion of the study, an average of 4 months)Enrollment:Target 75Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2026Testosterone cypionateCastration Resistant Metastatic Prostate CancerNCT04363164

Primary: Clinical or Radiographic Progression free survival (Up to 2 years)Enrollment:Target 150Sites: 6RANDOMIZED, TREATMENT

Phase 2Aug 1, 2026AmputationNCT04839497

Primary: Safety assessment of complications and adverse events associated with Volar Fibroblast injections (3 months from the injection visit)Enrollment:Target 20Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 3Q3 2026BupivacainePostoperative PainNCT06989866

Primary: Use of Opiate Pain Medications After Rhinoplasty (1 week)Enrollment:Target 50Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 2Aug 15, 2026pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA VaccineAnatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8NCT04329065

Primary: Enumeration of the number of T-bet+, CD4+, and CD8+ T-cells in tumor infiltrating lymphocytes (TIL) after combination immune-chemotherapy (Up to completion of surgical resection)Enrollment:Target 25Sites: 1NA, TREATMENT

Phase 3Aug 15, 2026RifampicinSevere Acute Malnutrition, HIV, Comorbidities and Coexisting ConditionsNCT05994742

Primary: Death or first hospitalisation or failed nutritional recovery within 24 weeks post-randomisation (24 weeks post-randomisation)Enrollment:674/674Sites: 9RANDOMIZED, TREATMENT

Phase 2Q3 2026SemaglutideCardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFp EF), ObesityNCT05371496

Primary: Pulmonary Capillary Wedge Pressure (PCWP) (Baseline, 12 months)Enrollment:81/81Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Aug 31, 2026Neuromuscular Blocking AgentsRespiratory Distress Syndrome, AdultNCT04545424

Primary: 28-day ventilator-free days (VFDs) (Calculated at study day 28 or death (whichever occurs first))Enrollment:Target 340Sites: 19RANDOMIZED, TREATMENT

Phase 2Q3 2026CeralasertibGynaecological CancersNCT04065269

Primary: Confirmed overall objective response rate (complete or partial response) as defined by RECIST version 1.1. (From start of treatment until treatment discontinuation - minimum follow-up of 16 weeks (if not progressed earlier), up to max study period (estimated 36 months).)Enrollment:Target 174Sites: 9NON_RANDOMIZED, TREATMENT

Phase 2Q3 2026AspirinVestibular Schwannoma, Acoustic Neuroma, Neurofibromatosis 2NCT03079999

Primary: Progression Free Survival (Progression, or around 3.5 years)Enrollment:97/97Sites: 5RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Sep 1, 2026SildenafilScleroderma, Mildly Elevated Pulmonary PressuresNCT04797286

Primary: Difference in change in distance walked in 6 minute walk test (6MWT) at 4 months (Baseline and 4 months)Enrollment:Target 30Sites: 2RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Sep 28, 2026Mesenchymal Stromal CellsCorneal UlcerNCT05705024

Primary: Improvement of Corneal Epithelial Barrier and/or Integrity (Efficacy Rate) (Day 28)Enrollment:Target 38Sites: 4RANDOMIZED, DOUBLE, TREATMENT

Phase 2Sep 29, 2026BXCL501 (dexmedetomidine HCl)Acute Stress Reaction, Acute Stress Disorder, Post-traumatic Stress DisorderNCT06943404

Primary: Change in ASD Score (Week 1, 3 after MVC)Enrollment:Target 100Sites: 3RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3Q3 2026Infections, Infected Wound, Nonunion of FractureNCT05699174

Primary: Number of patients with a hospital re-admission (1 year)Enrollment:Target 250Sites: 13RANDOMIZED, TREATMENT

Phase 3Sep 30, 2026Post Operative Surgical Site InfectionNCT04678154

Primary: Deep surgical site infection (180 days from final wound closure/cloverage)Enrollment:Target 600Sites: 31RANDOMIZED, TREATMENT

Phase 2Sep 30, 2026BoNT ATraumatic Brain InjuryNCT06293300

Primary: Change in photophobia measured by Numerical Rating Scale (Baseline, 6-weeks post-intervention, and 12-weeks post-intervention.)Enrollment:Target 50Sites: 1NA, TREATMENT

Phase 2Sep 30, 2026Breast Cancer RecurrentNCT05464082

Primary: Proportion of cases where clinically actionable therapies were identified by FPO. (up to 3 years)Enrollment:Target 80Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Oct 1, 2026EvolocumabMetastatic Renal Cell CarcinomaNCT06284564

Primary: Safety and adverse events (AEs) (Through study completion; an average of 1 year)Enrollment:10/10Sites: 2NA, TREATMENT

Phase 2Q4 2026Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung CancerNCT07104630

Primary: Change in functional capacity of LCS with advanced NSCLC, as measured by the 6-minute walk test (6MWT) (Baseline, 8 weeks)Enrollment:Target 85Sites: 1RANDOMIZED, SUPPORTIVE_CARE

Phase 2Nov 30, 2026SiltuximabSchwannomatosis, Schwannomas, Pain, ChronicNCT05684692

Primary: Change in worst pain intensity for each drug sub-study (Baseline to week 12)Enrollment:Target 40Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2026BevacizumabRecurrent Glioblastoma, Recurrent WHO Grade 4 GliomaNCT06160206

Primary: Overall survival (OS) (Time until death from any cause, assessed up to 9 months after registration)Enrollment:Target 134Sites: 3RANDOMIZED, TREATMENT

Phase 2Dec 1, 2026Advair HFAAltitude EdemaNCT06040268

Primary: VO2 max (day 3 of treatment)Enrollment:Target 60Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Dec 30, 2026Anti-CD40 Agonist Monoclonal Antibody CDX-1140Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous AdenocarcinomaNCT05231122

Primary: Incidence of adverse events (Up to 2 years)Enrollment:Target 80Sites: 2RANDOMIZED, SINGLE, TREATMENT

Phase 2Q4 2026DegarelixProstate CancerNCT04989946

Primary: Pathological Complete Response Rate (pCR) (at prostatectomy (up to 3 months))Enrollment:57/57Sites: 1RANDOMIZED, TREATMENT

Phase 2Q4 2026AZD6738Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRDNCT03740893

Primary: Cohorts B and C co-primary endpoint #1: Change in mean proliferation index (as measured by tumour cell Ki67 staining) post WOP intervention within post-treatment biopsy compared to pre-treatment baseline biopsy. (Post 2 weeks of trial treatment in the window of opportunity)Enrollment:Target 119Sites: 6NON_RANDOMIZED, OTHER

Phase 3Q4 2026600 mg IbuprofenTibial Fractures, PainNCT07006675

Primary: Secondary surgery to promote bone union after 3 months post initial surgery (1 year)Enrollment:Target 1,000Sites: 14RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2026ACIT-1Cancer, NeoplasmsNCT03096093

Primary: Toxicity (From start of treatment to 20 weeks.)Enrollment:Target 34Sites: 2NON_RANDOMIZED, TREATMENT

Phase 3Q4 2026RalinepagPAH, Pulmonary Hypertension, Pulmonary Arterial HypertensionNCT03683186

Primary: Number of subjects with treatment-emergent adverse events [Safety and Tolerability] (Up to 6 years)Enrollment:Target 1,000Sites: 190NA, TREATMENT

Phase 2Q4 2026pantoprazolePostoperative Nausea and VomitingNCT06488001

Primary: Postoperative Nausea and Vomiting (From enrollment until their postoperative visit at 6 weeks)Enrollment:Target 132Sites: 1RANDOMIZED, TRIPLE, PREVENTION

Phase 2Q4 2026CarboplatinHormone Refractory Prostate CancerNCT02955082

Primary: Radiographic Treatment Response (6 weeks)Enrollment:305/305Sites: 1NA, TREATMENT

Phase 2Dec 31, 2026Pembrolizumab (200mg IV for 30 minutesBreast CancerNCT03804944

Primary: Tolerability will be demonstrated if no grade 3 or higher toxicities are observed in the first 8 patients, of each arm. (3 years)Enrollment:Target 100Sites: 8RANDOMIZED, TREATMENT

Phase 2Jan 4, 2027DFMOProstate CancerNCT06059118

Primary: PSA response rate at Cycle 1 Day 64 (Cycle 1 Day 64 (each cycle is 119 days))Enrollment:Target 50Sites: 1NA, TREATMENT

Phase 2Jan 14, 2027Tranexamic AcidAnterior Cruciate Ligament ReconstructionNCT03552705

Primary: Synovial fluid IL-1 (Day 5)Enrollment:Target 50Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2027[11C]CPPC PET ligandALSNCT05602142

Primary: Safety of use of [11C]CPPC in patients with ALS as assessed by adverse events (Up to 180 days after scan)Enrollment:Target 20NA, DIAGNOSTIC

Phase 2Feb 26, 2027BrexanoloneAlcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)NCT06580444

Primary: Severity and numbers of treatment-emergent AEs (From onset of Brexanolone administration until 30-day follow up.)Enrollment:Target 40RANDOMIZED, TRIPLE, OTHER

Phase 2Q1 2027N-acetyl cysteineMultiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary ProgressiveNCT05122559

Primary: Safety and tolerability (15 months)Enrollment:Target 98Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2027CannabidivarinAutism Spectrum DisorderNCT03202303

Primary: Aberrant Behavior Checklist-Irritability (ABC-I) Subscale (Change from Baseline to Week 12 (Change over 12 weeks))Enrollment:Target 100Sites: 2RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Mar 31, 2027Ropivacaine injectionStress Disorders, Post-TraumaticNCT05889741

Primary: Change from baseline in Clinician-Administered PTSD Scale-DSM 5 (CAPS-5) (Baseline and at 1-month, 3-month, and 6-month follow-up assessments)Enrollment:Target 140Sites: 2RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2027Calcium GluconateTrauma, HemorrhageNCT05958342

Primary: Number of participants with 30-day mortality (from randomization to death or 30 days, whichever comes first)Enrollment:Target 1,050Sites: 18RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2027Sickle Cell DiseaseNCT05392894

Primary: Treatment failure or mortality (24 months post-randomisation)Enrollment:Target 120Sites: 1RANDOMIZED, TREATMENT

Phase 3Apr 30, 2027NicotinomideGlaucoma, Open-AngleNCT05405868

Primary: The difference between the treatment arms in change of Visual Field (VF) mean deviation (MD) at 27 months measured by the Humphrey Visual Field Analyser test (Month 27; end of trial treatment)Enrollment:Target 496Sites: 10RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2027allogeneic human mesenchymal stem cells (hMSCs)Non-ischemic Dilated CardiomyopathyNCT04476901

Primary: Change in LVEF (Baseline, 12 months)Enrollment:107/107Sites: 4RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3May 31, 2027Pembrolizumab 25 MG/ML [Keytruda]Lung Cancer, Nonsmall CellNCT05085028

Phase 3Q2 2027PaclitaxelSquamous Cell Carcinoma of the Penis, Usual TypeNCT02305654

Primary: Overall survival (up to 5 years)Enrollment:Target 200Sites: 17RANDOMIZED, TREATMENT

Phase 2Q2 2027UBT251Metabolic Dysfunction-associated Steatohepatitis (MASH)NCT07145151

Phase 2Jun 15, 2027Anti-HER2/HER3 Dendritic Cell VaccineAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast CarcinomaNCT04348747

Phase 2Q2 2027Niraparib oral capsuleOvarian Cancer RecurrentNCT05990192

Phase 2Jul 1, 2027Inhaled Treprostinil (Tyvaso Nebulizer)COPD (Chronic Obstructive Pulmonary Disease), HypoxemiaNCT07037836

Phase 2Jul 31, 2027PembrolizumabPancreatic CancerNCT05093231

Primary: Objective Response Rate (ORR) (Through study completion, an average of 2 years)Enrollment:Target 20Sites: 17NA, TREATMENT

Phase 3Jul 31, 2027IsoniazidTuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph NodeNCT06253715

Phase 2Aug 31, 20271. Intranasal oxytocin sprayAutism Spectrum Disorder, Bone HealthNCT05754073

Phase 2Sep 1, 2027Palbociclib 125Mg TabER+ Breast Cancer, HER2-negative Breast CancerNCT04985266

Phase 3Q3 2027UBT251 Injection 2.0 mgType 2 DiabetesNCT07659574

Phase 2Q3 2027Angiotensin (1-7)Traumatic Brain InjuryNCT06282965

Phase 3Q3 2027Diabetic Foot Ulcer (DFU)NCT07488247

Primary: Number of adverse event experienced by participants (03 months)Enrollment:Target 300Sites: 1RANDOMIZED, TREATMENT

Phase 2Oct 1, 2027NTX-001Peripheral Nerve InjuriesNCT04789044

Phase 2Oct 30, 2027177Lu girentuximabAdvanced Cancer, Clear Cell Renal Cell CarcinomaNCT05663710

Phase 2Q4 2027225Ac-J591Prostate CancerNCT04946370

Phase 3Q4 2027PlaceboProgressive Pulmonary Fibrosis, Interstitial Lung DiseaseNCT05943535

Phase 2Q4 2027Metformin + Standard of CareFocal Segmental GlomerulosclerosisNCT06090227

Phase 2Dec 2, 2027autologous skin fibroblastsWounds and InjuriesNCT01964859

Phase 3Dec 31, 2027Direct-Acting Oral Anticoagulants (used as per local standard practice)Traumatic Intracranial HaemorrhageNCT06322953

Phase 3Dec 31, 2027Cladribine (MAVENCLAD®)Advanced Multiple Sclerosis, Progressive Multiple SclerosisNCT04695080

Phase 2Q4 2027Tesamorelin 2 Milligrams (MG)Peripheral Nerve InjuriesNCT03150511

Phase 3Q4 2027PharmaNord Bio-Quinone Active CoQ10 Gold 100mgGulf War Syndrome, Persian Gulf Syndrome, Mitochondrial Disorder, Respiratory ChainNCT06515184

Phase 3Q1 2028UBT251 Injection 2.0 mg groupType 2 DiabetesNCT07653477

Phase 2Mar 1, 2028Psilocybin (Usona Institute)Spinal Cord Injury, Depression - Major Depressive Disorder, VeteranNCT07251491

Phase 2Apr 1, 2028Autologous Skin FibroblastsAmputation, Skin Wound, Stem CellNCT03947450

Phase 2Jun 4, 2028Colorectal Cancer, Bladder CancerNCT06528990

Phase 2Q2 2028Hydrogen PeroxideBreast CancerNCT03946202

Phase 3Q2 2028Prostate CancerNCT05613023

Phase 3Q3 2028Ketamine HydrochlorideTraumatic InjuryNCT05437575

Phase 2Aug 31, 2028Atorvastatin CalciumTraumatic Brain InjuryNCT05826912

Phase 2Sep 1, 2028Enfortumab vedotinMetastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Advanced Urothelial CarcinomaNCT07221942

Phase 3Q3 2028Autonomic Nervous System Disease, Concussive Injury, Mild Traumatic Brain InjuryNCT07071350

Phase 2Sep 30, 2028Propranolol HydrochloridePostoperative Chylothorax, Congenital Heart Disease, Open Heart SurgeryNCT06833320

Phase 2Oct 1, 2028RoginolisibLeukemia, Relapsed Leukemia, Chronic Lymphocytic LeukemiaNCT06644183

Phase 2Q4 2028L-citrullinePost Deployment Related Asthma, AsthmaNCT05259904

Phase 2Q4 202810 GE XenokidneyESRD (End-Stage Renal Disease), Kidney Transplantation, XenotransplantationNCT06878560

Phase 2Q4 2028bomedemstatMyelofibrosisNCT07424950

Phase 2Q4 2028PropranololAutism Spectrum Disorder, Challenging Behaviour, AggressionNCT07091279

Phase 2Dec 31, 2028Cord blood transplantation + conditioning + granulocytes of variable days according to study designAcute Myeloid Leukemia, Stem Cell Transplantation, Stem Cell Transplantation, HematopoieticNCT07372885

Phase 2Dec 31, 2028Carboplatin plus PaclitaxelOvarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CarcinomaNCT07023484

Phase 3Q4 2028Venetoclax 400Acute Myeloid LeukemiaNCT07075016

Phase 2Q4 2028Universal Donor (UD) TGFβi NK CellsNeuroblastomaNCT06450041

Phase 2Q4 2028DexamethasoneLymphoblastic LeukemiaNCT05848687

Phase 2Q1 2029PaxalisibMalignant Primary Gliomas, Glioblastoma Multiforme (GBM)NCT07391215

Phase 2Mar 1, 2029PT150PTSD - Post Traumatic Stress DisorderNCT07187011

Phase 3Mar 29, 2029Hematologic MalignanciesNCT07186192

Phase 2Mar 30, 2029FluorouracilClinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8NCT05651594

Phase 3Q1 2029UBT251Obstructive Sleep Apnea, ObesityNCT07806851

Phase 2Q2 2029Amyotrophic Lateral Sclerosis (ALS), Chronic Respiratory Failure, Neuromuscular Disease PatientsNCT07071935

Phase 2Jun 30, 2029Long COVID, Long COVID Syndrome, Long COVID-19 SyndromeNCT06940609

Phase 2Q3 2029AvutometinibGlioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-MutantNCT06630260

Phase 2Q4 2029SX-682Metastatic Castrate-Resistant Prostate Cancer (m CRPC)NCT07002320

Primary: Biologically active and tolerable dose range (From start of treatment to end of Cycle 2 Day 1 (each cycle is 28 days))Enrollment:Target 78Sites: 4NON_RANDOMIZED, TREATMENT

Phase 2Q4 2029GGTA1 KO ThymokidneyESRD (End-Stage Renal Disease), Kidney Transplantation, XenotransplantationNCT07224763

Phase 3Dec 13, 2029RevumenibAcute Myeloid Leukemia, AdultNCT06652438

Phase 2Q4 2029LenalidomideRecurrent Mantle Cell Lymphoma, Refractory Mantle Cell LymphomaNCT05910801

Phase 2Q4 2029EpcoritamabDiffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaNCT06238648

Phase 2Q1 20303,4-Methylenedioxymethamphetamine (MDMA)Post Traumatic Stress DisorderNCT07288151

Phase 3Q1 2030Valproic Acid (VPA)Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain InjuryNCT07166393

Phase 2Q1 2030UI-102Advanced CancerNCT07605962

Phase 3Q2 2030PlasmaBurn Injury, Thermal BurnNCT07212998

Phase 3Q2 2030CHIKV VLP vaccineChikungunya VirusNCT07467707

Phase 2Q3 2030UBT251Obesity &Amp; Overweight, Chronic Kidney DiseaseNCT07134335

Phase 2Jul 31, 2030Radiation: 131I-MIBGNeuroblastomaNCT07261241

Phase 3Q4 2030AbemaciclibBreast Cancer FemaleNCT04584853

Phase 2Nov 1, 2030Selpercatinib MonotherapyDifferentiated Thyroid Cancer, Pediatric Cancer, CancerNCT06458036

Phase 2Mar 30, 2031Abiraterone acetateProstate Cancer (Adenocarcinoma), Metastatic Prostate CancerNCT06616597

Phase 3Q2 2031Parkinsons Disease (PD)NCT07207057

Phase 3Jun 1, 2031paclitaxelGerm Cell Tumor, Teratoma, ChoriocarcinomaNCT02375204

Phase 2Aug 1, 2031IpilimumabLocally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell CarcinomaNCT06866262

Phase 2May 31, 2032ZumsemetinibHormone Receptor Positive HER-2 Negative Metastatic Breast CancerNCT06374459

Phase 3Dec 20, 2033Cervical Carcinoma, Adenocarcinoma, Adenosquamous CarcinomaNCT05581121

United Therapeutics Corporation

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent News & Research

Recent Insider Activity

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research